Contract research organization Chiltern announced today that it is expanding its Japanese and Asian presence through its purchase of Integrated Development Associates.
Financial terms of the deal were not disclosed.
IDA has staff in Japan, Korea and Southeast Asia – and offers opportunities to integrate the region into global drug development, according to Chiltern. IDA’s expertise includes establishing regulatory and development pathways in Japan, and implementing clinical trials across Asia.
“The acquisition of IDA is driven by our commitment to establish a substantial presence in all major global markets and support our clients with clinical development capabilities worldwide,” Chiltern CEO Jim Esinhart said in a news release. “Japan and Southeast Asia are among the world’s largest and fastest-growing pharmaceutical markets. IDA will enable us to grow in the APAC region through well-established relationships and local expertise and knowledge.”
“Japan and Southeast Asia are among the world’s largest and fastest-growing pharmaceutical markets. IDA will enable us to grow in the APAC region through well-established relationships and local expertise and knowledge,” Esinhart said.
IDA will continue as a wholly owned subsidiary of Chiltern, with IDA’s founder and CEO John Winebarger continuing to lead IDA as part of Chiltern’s leadership team.
Chiltern has more than 4,300 employees located across 47 countries.
[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]
